Clinical trial Recruiting at 13 sites Phase 3 Interventional Ages 18 and up

Comparing different doses of tenecteplase for treating acute ischemic stroke

Official title: A Multicentre, Prospective, Randomized, Open Label, Blinded-endpoint Trial to Optimize the Use of Intravenous Tenecteplase in Participants With Acute Ischemic Stroke (ACT-GLOBAL THROMBOLYSIS (ACT WHEN-001) Within A Multi-faCtorial, mulTi-arm, Multi-staGe, Randomised, gLOBal Adaptive pLatform Trial for Stroke (ACT-GLOBAL) NCT06352632

Run by University of Calgary · NCT06320431 · Data updated 2026-11-12

This study is testing whether a standard dose or a lower dose of a medication called tenecteplase can help people who have had an acute ischemic stroke recover better and stay safe.

Quick facts

PhasePhase 3
Study typeInterventional
Ages18 Years and up
SexAll
Enrollment4000 (estimated)
SponsorUniversity of Calgary
Academic / other
Locations24 sites (Sydney, Barangaroo and 23 other locations)
StatusRecruiting
StartedSeptember 26, 2024
Main results expectedSeptember 30, 2030
Study endsDecember 31, 2030
Registry record updatedOctober 21, 2026
Trial IDNCT06320431 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates include patients with disabling acute ischemic stroke who present within 4.5 hours of symptom onset and may benefit from intravenous thrombolysis.

Probably not a fit

Patients with absolute contraindications for intravenous thrombolysis or those experiencing minor strokes with non-disabling symptoms may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial aims to evaluate the effectiveness of standard-dose versus low-dose intravenous tenecteplase in patients with acute ischemic stroke. It employs a randomized, controlled, open-label design with blinded endpoint assessment, enrolling up to 4,000 patients who present to hospitals within 4.5 hours of symptom onset. Participants will be followed for 90 days to assess outcomes related to stroke recovery and safety. The trial also investigates the use of tenecteplase in conjunction with endovascular thrombectomy when necessary.

Why it matters

Potential benefit: If successful, this study could lead to optimized dosing of tenecteplase, improving recovery outcomes for patients with acute ischemic stroke.

How similar studies have gone: Previous studies have shown promising results with tenecteplase, indicating its potential efficacy compared to alteplase, making this approach both relevant and timely.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

1. All patients with disabling AIS presenting within 4.5 hours of symptom onset or last known well who may benefit from intravenous thrombolysis (IVT) with tenecteplase. Patients potentially eligible for IVT with conditions described as relative contraindications in national guidelines where physician discretion is recommended are eligible. Patients who received a DOAC, and those planned for emergency EVT are eligible.
2. Consent process completed as per national laws and regulation and the applicable ethics committee requirements.

Exclusion Criteria:

1. Any absolute contraindication for IV thrombolysis per current national guidelines. Examples include those who are actively bleeding, had recent intracranial surgery, head trauma, intracranial or subarachnoid hemorrhage, or a bleeding diathesis.
2. Minor stroke patients with non-disabling symptoms.

Where it's running

  • Royal Prince Alfred Hospital
    Sydney, New South Wales, Australia
    Recruiting
  • Monash University (Box Hill)
    Melbourne, Victoria, Australia
    Recruiting
  • University of Calgary
    Calgary, Alberta, Canada
    Recruiting
  • University of Alberta
    Edmonton, A, Canada
    Recruiting
  • University of British Columbia
    Vancouver, British Columbia, Canada
    Recruiting
  • University of Manitoba - Winnipeg Health Science Centre
    Winnipeg, Manitoba, Canada
    Recruiting
Show 18 more locations
  • Health Sciences North Horizon Sante-Nord
    Greater Sudbury, Ontario, Canada
    Recruiting
  • McMaster University Hamilton Health Sciences Centre
    Hamilton, Ontario, Canada
    Recruiting
  • Ottawa Hospital Research Institute
    Ottawa, Ontario, Canada
    Recruiting
  • St. Michael's Hospital
    Toronto, Ontario, Canada
    Recruiting
  • Sunnybrook Health Science Centre
    Toronto, Ontario, Canada
    Recruiting
  • Queen Elizabeth Hospital (PEI)
    Charlottetown, Prince Edward Island, Canada
    Recruiting
  • Royal University Hospital
    Saskatoon, Saskatchewan, Canada
    Recruiting
  • The George Institute for Global Health
    Sydney, Barangaroo, Australia
    Not yet recruiting
  • Medicine Hat Regional Hospital
    Medicine Hat, Alberta, Canada
    Not yet recruiting
  • Red Deer Regional Hospital
    Red Deer, Alberta, Canada
    Not yet recruiting
  • Kelowna Regional Hospital
    Kelowna, British Columbia, Canada
    Not yet recruiting
  • Royal Columbian Hospital
    New Westminster, British Columbia, Canada
    Not yet recruiting
  • Brandon Regional Hospital
    Brandon, Manitoba, Canada
    Not yet recruiting
  • Queen Elizabeth II Health Science Center (Halifax)
    Halifax, Nova Scotia, Canada
    Not yet recruiting
  • Kingston General Hospital
    Kingston, Ontario, Canada
    Not yet recruiting
  • Lawson Health Research Institute- London
    London, Ontario, Canada
    Not yet recruiting
  • Centre Hospitalier de l'Université de Montréal (CHUM)
    Montreal, Quebec, Canada
    Not yet recruiting
  • CIUSSS de l'Estrie - CHUS Fleurimont Hôpital (Sherbrooke)
    Sherbrooke, Quebec, Canada
    Not yet recruiting

Study contacts

  • Principal investigator: Bijoy K Menon, MD, MSc — University of Calgary
  • Study coordinator: Bijoy K Menon, MD, MSc
  • Email: bkmmenon@ucalgary.ca
  • Phone: 4039448107

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

  • One-stop approach for rapid start of endovascular clot removal

    This trial will test whether taking eligible adults with suspected large- or medium-vessel ischemic stroke straight to the angiography suite for imaging and treatment gets clot-removal therapy started faster and improves outcomes.

    Recruiting Paracelsus Medical University · Nuremberg and 1 other locations · NCT07052045

  • Effectiveness of a new neurorehabilitation technology for stroke recovery

    This study is testing a new rehabilitation technology that uses robots and virtual reality to see if it can help stroke patients recover better than regular therapy.

    Recruiting Neurotechnika · Samara, Samara Oblast · NCT06753006

  • Music therapy after stroke

    This trial tests whether adding music therapy to standard care helps stroke patients sleep better and feel less anxious or depressed while in the hospital.

    Recruiting Universidad de Granada · Granada, Granada · NCT07899034

  • Mobilisation After Endovascular Stroke Treatment

    This study checks whether moving around 12 hours after endovascular stroke treatment is as safe as moving around 24 hours for people with an acute ischemic stroke.

    Recruiting at 2 sites Karolinska Institutet · Tampere and 1 other locations · NCT07860333

  • Endovascular therapy plus standard care vs standard care alone for distal and medium vessel strokes

    In people with acute ischemic stroke due to distal or medium vessel blockages, this study tests whether adding endovascular treatment to the usual medical care helps improve outcomes compared with medical care alone.

    Recruiting Hospital Universitari Vall d'Hebron Research Institute · Barcelona, Barcelona · NCT07843797

  • Inter-Limb Transfer after Acute Stroke

    This study tests whether practicing motor skills with the affected arm helps improve movement in the other arm after an acute stroke.

    Recruiting at 2 sites University Hospital of Mont-Godinne · Yvoir, Namur and 1 other locations · NCT07822633

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.